New drug cocktail aims to boost lung cancer treatment before radiation
NCT ID NCT07643350
First seen Jun 17, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This Phase 2 trial tests whether adding two drugs (benmelstobart and anlotinib) to standard chemotherapy before chemoradiation helps people with stage III lung cancer that cannot be removed by surgery. 152 participants will be randomly assigned to receive either the new induction therapy followed by chemoradiation and maintenance immunotherapy, or chemoradiation followed by maintenance immunotherapy alone. The study will track how long the cancer stays under control and look for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ThirdXiangyaHCSU
Changsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Benmelstobart (an immunotherapy drug) and anlotinib (a targeted therapy drug), plus chemotherapy
What this could lead to
If successful, this approach could improve how long people with advanced lung cancer live without their disease getting worse, and may point to a more effective treatment plan.
What could go wrong
This is an early Phase 2 trial with only 152 people, so results are not definitive. Adding more drugs before radiation may increase side effects without clear benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.